Methods of obtaining a specific binding member that binds eotaxin
AssigneeMedImmune, LLC
InventorsTristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
Life of this patent
Estimating the term…
Abstract
Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
Claims12
A method of producing an antibody heavy chain variable region (VH) domain, the method comprising culturing host cells under conditions for production of said VH domain, wherein said host cells are transformed with a nucleic acid which comprises a nucleotide sequence encoding a polypeptide comprising a VH domain, wherein said VH domain comprises VH CDRs 1-3 with the amino acid sequences of SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, respectively, and wherein when the VH domain is paired with an antibody light chain variable region (VL) domain comprising VL CDRs 1-3 with the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, an antibody antigen binding site that binds eotaxin is provided.
A method of producing an antibody light chain variable region (VL) domain, the method comprising culturing host cells under conditions for production of said VL domain, wherein said host cells are transformed with a nucleic acid which comprises a nucleotide sequence encoding a polypeptide comprising a VL domain, wherein said VL domain comprises VL CDRs 1-3 with the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, and wherein when the VL domain is paired with an antibody heavy chain variable region (VH) domain comprising VH CDRs 1-3 with the amino acid sequences of SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, respectively, an antibody antigen binding site that binds eotaxin is provided.
Dependencies are inferred from the claim text.